By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exact Sciences today said that it expects to raise approximately $17.6 million through a public offering of 4.2 million shares of its common stock priced at $4.50 per share.

The Madison, Wis.-based molecular diagnostics firm said that if the underwriters of the offering exercise the option to purchase an additional 630,000 shares, it would receive total net proceeds of around $20.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.